PM
LENZ

Prosight Management’s LENZ Therapeutics LENZ Stock Holding History

Prosight Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-59,542
Closed -$1.03M – 61
2024
Q2 		$1.03M Sell
59,542
-5,458
-8% -$95.3K 0.31% 39
2024
Q1 		$1.45M Sell
65,000
-128,134
-66% -$2.66M 0.4% 36
2023
Q4 		$3.54M Buy
193,134
+2,016
+1% +$33.3K 1.42% 18
2023
Q3 		$3.32M Sell
191,118
-51,739
-21% -$900K 1.05% 25
2023
Q2 		$4.42M Buy
242,857
+117,619
+94% +$2.35M 1.29% 24
2023
Q1 		$2.15M Sell
125,238
-5,699
-4% -$92.2K 1.02% 28
2022
Q4 		$3.04M Buy
130,937
+80,016
+157% +$1.85M 1.66% 20
2022
Q3 		$1.13M Buy
+50,921
New +$1.21M 0.61% 33

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Prosight Management's LENZ Position: Q3 2024 in Review

Prosight Management sold out of LENZ Therapeutics (LENZ) in Q3 2024, closing a stake of 59,542 shares — an estimated $1.03M sold.

Prosight Management first reported a position in LENZ in Q3 2022 and held it in 8 quarters. The position peaked at $4.42M in Q2 2023. 78 funds tracked by Wall St. Rank hold LENZ as of Q3 2024.

  • Prosight Management reported no remaining LENZ Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Prosight Management sold 59,542 LENZ Therapeutics shares in Q3 2024, an estimated $1.03M.
  • Prosight Management first reported a position in LENZ Therapeutics in Q3 2022 and held it in 8 quarters.
  • Prosight Management's LENZ Therapeutics position peaked at $4.42M in Q2 2023.
  • 78 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2024.

Based on Prosight Management's 13F filing for Q3 2024, filed 14 Nov 2024.